Zacks Investment Research upgraded shares of STEREOTAXIS INC (STXS) from NEUTRAL to OUTPERFORM on November 15, 2012, with a target price of $1.90.
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to allow physicians to navigate catheters, guidewires and stent delivery devices through the blood vessels and chambers of the heart to treatment sites.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on STEREOTAXIS INC (STXS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment